Kazia Therapeutics

KZIA Rare disease Lead: Phase 2 1 Biotech Distilled article ↓

Most recent annual filing: 2025-11-07

Catalyst timeline

Paxalisib glioblastoma filing2H 2026Paxalisib glioblastoma filing, 2H 2026, notable
Paxalisib HR trial start4Q 2026Paxalisib HR trial start, 4Q 2026, notable
Paxalisib colorectal Ph2 start1Q 2027Paxalisib colorectal Ph2 start, 1Q 2027, notable
Paxalisib colorectal enrollment done2027Paxalisib colorectal enrollment done, 2027, notable
NDL2 and MSETC IND filing2027NDL2 and MSETC IND filing, 2027, notable
Paxalisib TNBC corporate update2H 2027Paxalisib TNBC corporate update, 2H 2027, material
Paxalisib TNBC enrollment doneJul 2027Paxalisib TNBC enrollment done, Jul 2027, notable
Paxalisib HR topline2028Paxalisib HR topline, 2028, major
Paxalisib HR corporate update1H 2028Paxalisib HR corporate update, 1H 2028, material

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (10 active programs)

paxalisib

GDC-0084

Small Molecule Target: PI3K, Akt, mTOR

Glioblastoma Phase 2 oral Simcere NCT03522298
Triple-Negative Breast Cancer Phase 1 oral Simcere NCT03765983
Diffuse Intrinsic Pontine Glioma oral Simcere
Atypical Rhabdoid/Teratoid Tumors Phase 2 Simcere

NDL2

Peptide Target: PD-L1

Breast Cancer Preclinical QIMR Berghofer
Non-Small Cell Lung Cancer Preclinical QIMR Berghofer
Undisclosed indication Preclinical QIMR Berghofer Medical Research Institute

EVT801

Small Molecule Target: VEGFR3

Undisclosed indication Preclinical oral Evotec SE NCT05114668

MSETC

Peptide Target: SETDB1

Undisclosed indication Preclinical QIMR Berghofer

paxalisib

Small Molecule Target: PI3K/mTOR

Colorectal Cancer Preclinical

Technology platforms

PD-L1 Protein Degrader Platform

First-in-class optimized intracellular PD-L1 protein degrader platform; designed to overcome mechanisms of resistance to antibody-based checkpoint inhibitors; potential broad applicability across solid tumors and rationale for combination with pathway inhibitors and cytotoxics; IND-enabling studies commencing 2026

Targets: PD-L1

PD-L1 protein degrader platform · QIMR Berghofer

Bicyclic peptide-based PD-L1 protein degrader platform targeting intracellular PD-L1 to restore anti-tumor immune responses; focus on cancers exhibiting immune evasion or checkpoint inhibitor resistance. Lead compound: NDL2.

Targets: PD-L1

SETDB1-targeted epigenetic platform · QIMR Berghofer Medical Research Institute

Proprietary SETDB1 histone methyltransferase inhibition platform targeting cancer resistance mechanisms; SETDB1 overexpression suppresses immune signaling and drives resistance to immunotherapy; platform aims to restore immune function in tumors and enhance cancer treatment efficacy

Targets: SETDB1

SETDB1 Epigenetic Drug Development Platform · QIMR Berghofer

AI-integrated epigenetic drug discovery engine enabling rapid, precise, and scalable candidate generation targeting SETDB1-associated nuclear complexes; focus on restoring immune signaling in tumors resistant to immunotherapy across multiple solid tumor types

Targets: SETDB1

SETDB1 Inhibitor Platform

First-in-class optimized SETDB1 inhibitor platform targeting SETDB1, a key epigenetic regulator of immune evasion; designed to restore immune visibility in resistant tumors; applicable across solid tumors; IND-enabling studies commencing 2026

Targets: SETDB1

SETDB1 inhibitor platform · QIMR Berghofer

Bicyclic peptide-based SETDB1 inhibitor platform targeting SETDB1, a key epigenetic regulator of immune evasion in cancer. Lead compound: MSETC. In-licensed from QIMR Berghofer.

Targets: SETDB1

Biotech Distilled coverage (1)

2026-09-02 Kazia Therapeutics (KZIA) — Scientific Deep Dive for Paxalisib and Pipeline Products 🔒 Paid

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.